Vaccine Adjuvants Market Trends

Global Vaccine adjuvants Market Overview

The Vaccine Adjuvants Market Size was valued at USD 1.32 billion in 2023 and is projected to grow from USD 1.34 Billion in 2024 to USD 1.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.10% during the forecast period (2024 - 2032). Adjuvants are substances added into vaccines to improve the body's immune response to antigens. These have many different applications. The rising elderly and obese populations are the main reasons driving the market growth of the vaccine adjuvants. These are just a few of the market drivers that are driving the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In March 2024, Croda International signed an arrangement with the Access to Advanced Health Institute (AAHI) collaboration agreement in order to foster innovation and development of vaccine adjuvant formulations.

The Joint Science and Technology Office (JSTO) for Chemical and Biological Defense (CBD) Program at the United States Defense Threat Reduction Agency (DTRA) has awarded a five-year contract comprising program options worth up to $31m including to Ginkgo Bioworks Inc. And SaponiQx, Inc. the latter being a subsidiary of Agenus Inc awarding the team a 5-year contract totaling up to $31 million which includes program options in February 2024 to discover and develop next-generation vaccine adjuvants.

On November 2023, Novavax, Inc., announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) had received Emergency Use Listing (EUL) from the World Health Organization (WHO) for active immunization against COVID-19 in individuals aged 12 years and above.

January 2023: Elicio Therapeutics engineers lymph node-targeted adjuvants and vaccines for an array of highly malignant cancers as well as infectious diseases such as HIV and entered into a definitive merger deal with Angion Biomedica Corp with a focus on moving forward Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology for developing immunotherapies, especially ELI-002 therapeutic cancer vaccine targeting mKRAS-driven tumors.

November 2022: Hubro Therapeutics AS buys GM-CSF vaccine adjuvant from Targovax ASA under an asset purchase agreement paying cash of NOK10 million. Hubro continues the development of GM-CSF as an adjuvant for use with its pipeline of novel cancer vaccines.

May 2023 Exhorts USFDA to Approve Arexvy by GSK for RSV Infections in People Aged 60 and above. This will be the first-ever licensed RSV vaccine for adults over the age of sixty.

Seppic enters October 2023 with its new adjuvant, Montanide ISA 51. Montanide ISA 51 is currently under clinical development for a number of vaccines, including malaria and pneumococcal vaccines. Soligenix’s new Ribi adjuvant based on synthetic toll-like receptor 4 (TLR4) agonist has been presented as capable of increasing vaccine efficacy. Presently, Ribi is being developed clinically for a number of different vaccines, such as HIV vaccines & hepatitis B vaccines.

Vaccine Adjuvants Market Trends

• Increased prevalence of infectious diseases to propel market growth

During the projected period, an increase in the prevalence of infectious diseases around the world is anticipated to fuel market expansion for vaccine adjuvants. One of the best methods for the prevention of infectious diseases, for instance, is vaccination. Second only to COVID-19, tuberculosis (TB) is one of the deadliest infectious illnesses in the world, and drug-resistant TB strains continue to be a major concern. The World Health Organization (WHO) assesses that 1.6 million individuals worldwide will pass away from TB in 2021. TB is the second most fatal infectious disease in the world, behind COVID-19 and ahead of HIV/AIDS, and the 13th major cause of death globally. The worldwide market of vaccine adjuvants is anticipated to develop throughout the projected period due to increased adjuvant use in vaccines globally. For instance, vaccine adjuvants are used to boost the immune response of the vaccination as well as to induce a higher immune response in those who get the vaccine. According to the CDC, aluminum salts, including aluminum phosphate, aluminum hydroxide, and aluminum potassium sulfate, have reportedly been used safely in vaccinations for more than 70 years. Clinical trials are always conducted before adjuvant-containing vaccinations are licensed in the United States to ensure their effectiveness and safety. Thus, this factor is driving the market CAGR.

Players in the vaccine adjuvants market are expected to have considerable growth prospects due to the global COVID-19 (pandemic) outbreak. For instance, the usage of vaccine adjuvants has expanded globally, along with the increased focus on developing COVID-19 vaccines. The FDA gave an emergency use authorization (EUA) for the adjuvanted COVID-19 vaccine Novavax in July 2022 for people ages 18 and older. Coronavirus disease (COVID-19) is an infectious illness brought on by coronavirus two that causes severe acute respiratory syndrome (SARS-CoV-2). Government efforts and policies relating to immunization or immunization programs are anticipated to present substantial growth potential for industry participants in the worldwide market of vaccine adjuvants. For example, immunization is one of the world's most affordable public health initiatives, saving millions of lives yearly and shielding kids from disease and impairment. Through the Universal Immunization Program, the Indian government has carried out the largest immunization campaign in the world, focusing on 2.6 crore children and more than three crore pregnant women (UIP). The program will ensure that Routine Immunization (RI) services are provided to children who are unvaccinated or just partially immunized, as well as to expectant mothers worldwide. Thus, it is anticipated that this aspect will accelerate vaccine adjuvants market revenue globally.

Vaccine Adjuvants Market Segment Insights

Vaccine Adjuvants Type Insights

The Market segments of Vaccine Adjuvants, based on Type, includes pathogen components, particulate adjuvants, and Others. The particulate adjuvants segment held the majority share in 2022 in the Vaccine Adjuvants Market data. The adjuvant emulsion sector is anticipated to expand at the highest CAGR, while the particulate segment is anticipated to have the largest market share. The drivers include the increased incidence of conditions including allergies, cancer, and HIV/AIDS, the improvement of vaccine vaccination, and the growing need for cutting-edge treatment choices.

Vaccine Adjuvants Route of Administration Insights

The Vaccine Adjuvants Market segmentation, based on route of administration, includes oral, Intramuscular, Subcutaneous, And Intradermal. The intramuscular segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Due to the rising elderly population and vaccinations for better immunization, the intramuscular sector is anticipated to have the highest CAGR during the expected period and drive the vaccine adjuvants market.

Figure 2: Vaccine Adjuvants Market, by Route of Administration, 2023 & 2032 (USD Billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Vaccine Adjuvants End-User Insights

The Market data of Vaccine Adjuvants, based on end-user, includes pediatric, and adult. The pediatric segment dominated the vaccine adjuvants market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030.  The pediatric user held the major share of the vaccine adjuvants as infants and young children are one of the most vulnerable demographics and they are required to get their mandatory vaccine to fight the increasing prevalence of infectious diseases.

Vaccine Adjuvants Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America vaccine adjuvants market accounted for USD .595 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The presence of major market players, the availability of cutting-edge technology, and the rising expenditure in vaccine research and development are the primary factors propelling the vaccine adjuvants market's expansion in the North American area. Numerous immunization programs, government and non-government initiatives, and rising demand for combination vaccines all contribute to market growth. In the United States, for instance, retail pharmacies have reported administering and reporting more than 254.3 million doses across programs, including eight million doses given on-site to long-term care facilities in the early days of the vaccination program, per data published by the National Center for Immunization and Respiratory Diseases on June 9, 2022. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: VACCINE ADJUVANTS MARKET SHARE BY REGION 2023 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe vaccine adjuvants market accounts for the second-largest market share. The higher GDP per capita with governments and private sector investment in research and development to reach a major breakthrough are just a few of the causes that may be credited to the domination of the regional market. Moreover, UK market of vaccine adjuvants held the largest market share, and the Germany market of vaccine adjuvants was the fastest-growing market in the region.

Asia Pacific vaccine adjuvants Market is expected to grow at the fastest CAGR from 2022 to 2030. Due to the increasing deployment of optical interconnects in data centers and metro and long-haul networks, the Asia Pacific is predicted to have the highest data center interconnect market growth during the forecast period. Enterprise communications in China are being rapidly transformed by digital technologies and cloud computing, driving the demand for more scalable, flexible, and effective data center interconnect services. Further, the China market of vaccine adjuvants held the largest market share, and the India market of vaccine adjuvants was the fastest growing market in the region.

Vaccine Adjuvants Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of vaccine adjuvants grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the vaccine adjuvants industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global vaccine adjuvants industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, vaccine adjuvants industry has provided medicine with some of the most significant benefits. The vaccine adjuvants market major player such as Adjuvatis, GlaxoSmithKline PLC, Croda International PLC, Merck KGaA, TjKaiwei, OZ Biosciences.

GSK plc, formerly known as GlaxoSmithKline plc, is a multinational pharmaceutical and biotechnology business based in London, England. SmithKline Beecham and Glaxo Wellcome merged to form this company in 2000. Following encouraging Phase III clinical data, GSK and SK bioscience submitted a biologics licensing application to the Korean Ministry of Food and Drug Safety (KMFDS) for its SKYCovione in April 2022. It is a COVID-19 vaccine candidate made from recombinant proteins with pandemic adjuvant from GSK.

With its headquarters in Paris, France, Sanofi S.A. is a worldwide French pharmaceutical and healthcare corporation. The company was initially founded in 1973, then in 1999, and it combined with Synthélabo to form Sanofi-Synthélabo. Sanofi and GSK planned to present data from their Phase 3 effectiveness and booster trials in February 2022 to support regulatory applications for a COVID-19 vaccine.

Key Companies in the market of vaccine adjuvants includes

• Adjuvatis


• GlaxoSmithKline PLC


• Croda International PLC


• Merck KGaA


• TjKaiwei


• OZ Biosciences


• Brenntag Biosector


• MVP Laboratories


• Zhuoyue


• Aphios


• Novavax Inc.

Vaccine Adjuvants Industry Developments

November 2023Evonik Industries announces the launch of its new PhytoSquene adjuvant, a non-animal-derived squalene suitable for use in vaccines and other pharmaceutical applications. PhytoSquene is an amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It meets the demand for a secure commercial supply of non-animal-derived squalene.Dynavax Technologies announces the launch of its new CpG 1018 adjuvant, a synthetic toll-like receptor 9 (TLR9) agonist that has been shown to enhance the efficacy of vaccines. CpG 1018 is currently in clinical development for a variety of vaccines, including influenza, respiratory syncytial virus (RSV), and Zika virus.Invivogen announces the launch of its new PolyI:LC adjuvant, a synthetic double-stranded RNA (dsRNA) that has been shown to enhance the efficacy of vaccines. PolyI:LC is currently in clinical development for a variety of vaccines, including cancer vaccines and therapeutic vaccines.

October 2023

Seppic announces the launch of its new Montanide ISA 51 adjuvant, an oil-in-water emulsion that has been shown to enhance the efficacy of vaccines. Montanide ISA 51 is currently in clinical development for a variety of vaccines, including malaria vaccines and pneumococcal vaccines.Soligenix announces the launch of its new Ribi adjuvant, a synthetic toll-like receptor 4 (TLR4) agonist that has been shown to enhance the efficacy of vaccines. Ribi is currently in clinical development for a variety of vaccines, including HIV vaccines and hepatitis B vaccines.3M announces the launch of its new 3M Adjuvant System, a next-generation adjuvant system that has been shown to enhance the efficacy of vaccines. 3M Adjuvant System is currently in clinical development for a variety of vaccines, including COVID-19 vaccines and influenza vaccines.

Vaccine Adjuvants Market Segmentation

Vaccine Adjuvants Type Outlook (USD Billion, 2018-2030)

• Pathogen Components


• Particulate Adjuvants


• Others

Vaccine Adjuvants Route of Administration Outlook (USD Billion, 2018-2030)

• Oral


• Intramuscular


• Subcutaneous


• Intradermal

Vaccine Adjuvants End User Outlook (USD Billion, 2018-2030)

• Pediatric


• Adult

Vaccine adjuvants Regional Outlook (USD Billion, 2018-2030)

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America